- Trial phase
- Approved
- Time to market
- Already on the market (approved in US, EU, Japan, China, and other major markets)
- Why 4/10
- Cabenuva is already approved and commercialized with no pending PDUFA or pivotal readout scheduled in the next ~12 months. The defining binary catalysts (initial FDA approval 2021, every-two-month expansion 2022, adolescent indication expansion) have already passed. At GSK, a diversified large-cap pharma with a $51.65 stock price and broad portfolio, Cabenuva is one of many products and not a concentrated value driver, capping impactScore at 4.
Cabenuva is an established, approved product with no imminent binary catalyst, watch GSK for overall pharma sector trends, HIV market share shifts vs. oral competitors and Gilead's Sunlenca, and ViiV's quarterly sales disclosures rather than a single drug event.
Price Chart
Executive Summary
Cabenuva (cabotegravir + rilpivirine) is the first and only FDA-approved complete long-acting injectable regimen for HIV-1 treatment, developed by ViiV Healthcare (majority-owned by GSK). Originally approved in January 2021 for monthly dosing, the label was expanded in February 2022 to include every-two-month dosing and later to adolescents aged 12+. For GSK, a diversified global pharma giant (~$51.65/share, 52-week range $38.63-$61.70), Cabenuva is one asset within a broad portfolio and not a binary make-or-break driver. Recent 2026 data (LATITUDE Phase 3 superiority results published in NEJM, AIDS 2026 adolescent data) reinforce the drug's clinical profile but represent label-reinforcing evidence rather than new binary catalysts. The stock carries a "hold" consensus with 14 bullish/15 hold/3 sell analysts and a mean price target of $58.08, implying ~8.4% upside.
How It Works
Cabenuva is a two-drug injectable combination for HIV-1. One component (cabotegravir) blocks the virus from inserting its DNA into human cells. The other (rilpivirine) gums up the virus's reverse transcriptase enzyme, preventing it from copying its genetic material. Given as intramuscular shots every 1 or 2 months (after a short oral lead-in), it replaces the need for daily oral HIV pills.
Trial Status
Cabenuva is already FDA-approved (January 2021 for monthly, February 2022 for every-two-months, and expanded to adolescents). Recent 2026 data: the LATITUDE Phase 3 trial (final data February 2026, published in NEJM) showed Cabenuva was superior to daily oral therapy for maintaining viral suppression in people with adherence challenges. At AIDS 2026 (July 2026), data from the IMPAACT 2017 (MOCHA) study in adolescents showed 94.4% maintained viral suppression at week 96, with >97% preferring injections over daily pills.
The Two-Sided Case
Upcoming Catalysts
- No specific PDUFA or pivotal readout catalyst scheduled for Cabenuva in the next ~12 months; the drug is already approved and commercialized. Watch for quarterly ViiV/GSK sales disclosures, potential additional label expansions (e.g., younger pediatric populations), and competitive dynamics with Gilead's Sunlenca.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
GSK plc 6-K GSK ·Originating report